03:32 AM EDT, 09/24/2026 (MT Newswires) -- Scancell Holdings (SCLP.L) entered into a loan agreement worth up to $25 million with certain BlackRock-managed funds and accounts. The four-tranche loan carries an interest rate of 10.50% per annum and can be converted into ordinary shares. The company will use the loan to help support its phase 3 study for iSCIB1 and its planned Nasdaq listing. The clinical immuno-oncology company plans to draw down $7 million, subject to shareholder approval. The rest of the $8 million tranches will be drawn down after finalizing its US listing deals and the clinical site launch of its late-stage study.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.